Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 238,227,221 papers from all fields of science
Search
Sign In
Create Free Account
PKC412
Known as:
PKC 412
, PKC-412
A synthetic indolocarbazole protein kinase C (PKC) inhibitor. As a nonspecific inhibitor of protein kinase C enzymes, midostaurin inhibits oncogenic…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Narrower (1)
CGP41251
Broader (1)
midostaurin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis: Follow up of a single-center Italian compassionate use.
C. Papayannidis
,
S. Soverini
,
+16 authors
G. Martinelli
2014
Corpus ID: 78564785
7113 Background: Treatment of SM usually focuses on symptom relief by histamine receptor antagonists and other supportive therapy…
Expand
2014
2014
Abstract 746: PKC412 (Midostaurin) is safe and highly effective in systemic mastocytosis patients: Follow up of a single-center Italian compassionate use
C. Papayannidis
,
S. Soverini
,
+15 authors
G. Martinelli
2014
Corpus ID: 58741749
Introduction. Mastocytosis is a myeloid neoplasm characterized by abnormal accumulation and frequent activation of mast cells…
Expand
2013
2013
FLT 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
P. Wiernik
2013
Corpus ID: 37118967
634. 42. Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and…
Expand
2013
2013
respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Patients with acute myeloid leukemia and an activating mutation in FLT3
Jennifer J. Clark
,
D. Gilliland
,
+11 authors
S. Nimer
2013
Corpus ID: 165003161
doi:10.1182/blood-2004-03-0891Prepublished online September 2, 2004;2005 105: 54-60€€€€Jennifer Clark, D. Gary Gilliland and…
Expand
2008
2008
Hématologie maligne
N. Mounier
ONCOLOGIE
2008
Corpus ID: 45686597
En hématologie maligne, les scoops sont, en général, réservés au congrès de l’ASH en décembre, mais l’ASCO, en juin, fournit une…
Expand
2008
2008
Genetics: In the driving seat
Simone Alves
Nature Reviews. Cancer
2008
Corpus ID: 37151357
membrane and kinase domains of the receptor tyrosine kinase FLT3 are known to be leukaemogenic, but can other mutations in FLT3…
Expand
2004
2004
A combination of histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC and AML cells with constitutively active mutant FLT-3 tyrosine kinase.
K. Bhalla
,
P. George
,
+7 authors
P. Atadja
Journal of Clinical Oncology
2004
Corpus ID: 19453567
6541 Background: We have reported that treatment with histone deacetylase inhibitors, LAQ824 and LBH589 (Novartis Pharma AG), and…
Expand
2003
2003
PKC412, inhibitor of the KIT tyrosine kinase, demonstrates efficacy in mast cell leukemia with the D816V KIT mutation.
J. Gotlib
,
C. Berubé
,
+10 authors
S. Coutre
2003
Corpus ID: 90447126
2000
2000
Dragons 'Round the Fleece Again: STI571 Versus α1 Acid Glycoprotein
E. Sausville
2000
Corpus ID: 9209012
Ovid recounts the story of Jason and his Argonauts (1), who, after dealing with jealous harpies, wandering rocks, spectral armies…
Expand
1999
1999
Le PKC 412
A. Lansiaux
,
D. Fabbro
,
T. J. Meyer
,
François Hamy
,
C. Bailly
1999
Corpus ID: 71132078
Le PKC 412 (figure 1) denomme precedemment CGP 41251, developpe par les laboratoires Novartis (Bâle, Suisse), est un inhibiteur…
Expand